138 related articles for article (PubMed ID: 28462920)
1. Evaluating the association of single-nucleotide polymorphisms with tenofovir exposure in a diverse prospective cohort of women living with HIV.
Baxi SM; Greenblatt RM; Bacchetti P; Cohen M; DeHovitz JA; Anastos K; Gange SJ; Young MA; Aouizerat BE
Pharmacogenomics J; 2018 Apr; 18(2):245-250. PubMed ID: 28462920
[TBL] [Abstract][Full Text] [Related]
2. Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV.
Baxi SM; Scherzer R; Greenblatt RM; Minkoff H; Sharma A; Cohen M; Young MA; Abraham AG; Shlipak MG;
AIDS; 2016 Feb; 30(4):609-18. PubMed ID: 26558723
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetic Modeling of Tenofovir in the Genital Tract of Male HIV-Infected Patients.
Valade E; Bouazza N; Lui G; Illamola SM; Benaboud S; Treluyer JM; Cobat A; Foissac F; De Sousa Mendes M; Chenevier-Gobeaux C; Suzan-Monti M; Rouzioux C; Assoumou L; Viard JP; Urien S; Ghosn J; Hirt D
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956420
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with daily tenofovir exposure in Thai subjects taking combination antiretroviral therapy.
Kerr SJ; Punyawudho B; Thammajaruk N; Colbers A; Chaiyahong P; Phonphithak S; Sapsirisavat V; Ruxrungtham K; Burger DM; Avihingsanon A
AIDS Res Hum Retroviruses; 2015 Apr; 31(4):368-74. PubMed ID: 25384393
[TBL] [Abstract][Full Text] [Related]
5. ABCG2 rs2231142 variant in hyperuricemia is modified by SLC2A9 and SLC22A12 polymorphisms and cardiovascular risk factors in an elderly community-dwelling population.
Liu J; Yang W; Li Y; Wei Z; Dan X
BMC Med Genet; 2020 Mar; 21(1):54. PubMed ID: 32183743
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Genetic Variants of the Kinases That Activate Tenofovir in a Compartment-specific Manner.
Lade JM; To EE; Hendrix CW; Bumpus NN
EBioMedicine; 2015 Sep; 2(9):1145-52. PubMed ID: 26501112
[TBL] [Abstract][Full Text] [Related]
7. Meconium Tenofovir Concentrations and Growth and Bone Outcomes in Prenatally Tenofovir Exposed HIV-Uninfected Children.
Himes SK; Wu JW; Jacobson DL; Tassiopoulos K; Hazra R; Kacanek D; Van Dyke RB; Rich KC; Siberry GK; Huestis MA;
Pediatr Infect Dis J; 2015 Aug; 34(8):851-7. PubMed ID: 25961889
[TBL] [Abstract][Full Text] [Related]
8. Interactions of tenofovir and tenofovir disoproxil fumarate with drug efflux transporters ABCB1, ABCG2, and ABCC2; role in transport across the placenta.
Neumanova Z; Cerveny L; Ceckova M; Staud F
AIDS; 2014 Jan; 28(1):9-17. PubMed ID: 24413260
[TBL] [Abstract][Full Text] [Related]
9. Methotrexate Decreases Tenofovir Exposure in Antiretroviral-Suppressed Individuals Living With HIV.
Gingrich D; Deitchman AN; Kantor A; Huang L; Stein JH; Currier JS; Hsue PY; Ribaudo HJ; Aweeka FT;
J Acquir Immune Defic Syndr; 2020 Dec; 85(5):651-658. PubMed ID: 33177476
[TBL] [Abstract][Full Text] [Related]
10. Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics.
Gini J; Olagunju A; Dickinson L; Waitt C; Neary M; Else LJ; Siccardi M; Khoo S
Pharmacogenomics; 2019 Mar; 20(4):217-223. PubMed ID: 30767719
[TBL] [Abstract][Full Text] [Related]
11. A Comparison of Plasma Efavirenz and Tenofovir, Dried Blood Spot Tenofovir-Diphosphate, and Self-Reported Adherence to Predict Virologic Suppression Among South African Women.
Phillips TK; Sinxadi P; Abrams EJ; Zerbe A; Orrell C; Hu NC; Brittain K; Gomba Y; Norman J; Wiesner L; Myer L; Maartens G
J Acquir Immune Defic Syndr; 2019 Jul; 81(3):311-318. PubMed ID: 30893125
[TBL] [Abstract][Full Text] [Related]
12. Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients.
Kiser JJ; Aquilante CL; Anderson PL; King TM; Carten ML; Fletcher CV
J Acquir Immune Defic Syndr; 2008 Mar; 47(3):298-303. PubMed ID: 18398970
[TBL] [Abstract][Full Text] [Related]
13. Single-nucleotide polymorphisms in ABC drug transporters alter expression and circulating tenofovir in healthy South African women exposed to pre-exposure prophylaxis.
Zondo NM; Sobia P; Sivro A; Ngcapu S; Mansoor LE; Mahomed S; Lewis L; Ramsuran V; Archary D
Pharmacogenomics; 2023 Jul; 24(11):599-613. PubMed ID: 37503696
[No Abstract] [Full Text] [Related]
14. Does tenofovir influence efavirenz pharmacokinetics?
Rotger M; Colombo S; Furrer H; Décosterd L; Buclin T; Telenti A
Antivir Ther; 2007; 12(1):115-8. PubMed ID: 17503755
[TBL] [Abstract][Full Text] [Related]
15. The Vaginal Microbiome and its Potential to Impact Efficacy of HIV Pre-exposure Prophylaxis for Women.
Velloza J; Heffron R
Curr HIV/AIDS Rep; 2017 Oct; 14(5):153-160. PubMed ID: 28812207
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of oral tenofovir disoproxil fumarate in pregnancy and lactation: a systematic review.
Bierhoff M; Smolders EJ; Tarning J; Burger DM; Spijker R; Rijken MJ; Angkurawaranon C; McGready R; White NJ; Nosten F; van Vugt M
Antivir Ther; 2019; 24(7):529-540. PubMed ID: 31868655
[TBL] [Abstract][Full Text] [Related]
17. Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis.
Pyra M; Anderson PL; Hendrix CW; Heffron R; Mugwanya K; Haberer JE; Thomas KK; Celum C; Donnell D; Marzinke MA; Bukusi EA; Mugo NR; Asiimwe S; Katabira E; Baeten JM;
AIDS; 2018 Aug; 32(13):1891-1898. PubMed ID: 29894385
[TBL] [Abstract][Full Text] [Related]
18. Short Communication: Association of Vitamin D Insufficiency and Protective Tenofovir Diphosphate Concentrations with Bone Toxicity in Adolescent Boys and Young Men Using Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Pre-Exposure Prophylaxis.
Havens PL; Tamhane A; Stephensen CB; Schuster GU; Gordon CM; Liu N; Wilson CM; Hosek SG; Anderson PL; Kapogiannis BG; Mulligan K
AIDS Res Hum Retroviruses; 2019 Feb; 35(2):123-128. PubMed ID: 30280906
[TBL] [Abstract][Full Text] [Related]
19. Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment.
Cressey TR; Avihingsanon A; Halue G; Leenasirimakul P; Sukrakanchana PO; Tawon Y; Jaisieng N; Jourdain G; Podany AT; Fletcher CV; Klinbuayaem V; Bowonwatanuwong C
Clin Infect Dis; 2015 Aug; 61(4):633-9. PubMed ID: 25921689
[TBL] [Abstract][Full Text] [Related]
20. Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy.
Klarica Domjanović I; Lovrić M; Trkulja V; Petelin-Gadže Ž; Ganoci L; Čajić I; Božina N
Br J Clin Pharmacol; 2018 Sep; 84(9):2106-2119. PubMed ID: 29791014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
